John Valliant - 01 Mar 2022 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Executive Officer, Director
Signature
/s/Maria Stahl as Attorney-in-Fact for John Valliant
Issuer symbol
FUSN
Transactions as of
01 Mar 2022
Transactions value $
-$205,201
Form type
4
Filing time
03 Mar 2022, 15:53:28 UTC
Previous filing
28 Feb 2022
Next filing
08 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FUSN Common Stock Sale -$6,242 -847 -0.2% $7.37 431,536 01 Mar 2022 Direct F1, F2
transaction FUSN Common Stock Sale -$197,502 -26,546 -6.2% $7.44 404,990 02 Mar 2022 Direct F1, F3
transaction FUSN Common Stock Sale -$1,456 -200 -0.05% $7.28 404,790 03 Mar 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.29 to $7.52 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.20 to $7.60 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.28 to $7.281 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.